NASDAQ
22.11.24
21:42 Uhr
1,810 US-Dollar
-0,040
-2,16 %
-2,16 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 122 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and... ► Artikel lesen | |
| 12.11. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Milestone Pharmaceuticals maintains Buy rating from TD Cowen | 2 | Investing.com | ||
| 14.10. | Wainwright maintains Buy rating on Milestone Pharma stock | 1 | Investing.com | ||
| 06.09. | Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China | 107 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 04.09. | Milestone Pharmaceuticals welcomes new board member Joseph Papa | 1 | Investing.com | ||
| 04.09. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.08. | Milestone Pharmaceuticals GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 08.08. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 90 | GlobeNewswire (Europe) | - NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed... ► Artikel lesen | |
| 08.08. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.07. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings from the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 2024 | 1 | GlobeNewswire (USA) | ||
| 31.05. | Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 29.05. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST | 225 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 13.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 173 | GlobeNewswire (Europe) | - NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR... ► Artikel lesen | |
| 08.04. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting | 153 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,610 | -0,02 % | Die Anleger von Moderna zittern vor Robert F. Kennedy, auch BioNTech gerät unter Druck, Pfizer folgt dem Beispiel und Novo Nordisk bekommt es mit immer mehr Konkurrenz zu tun | Rund zwei Monate vor dem Amtsantritt von Donald Trump nimmt dessen Kabinett langsam Formen an. Die Presse findet für die bisherigen Entscheidungen illustre Worte, sehr beliebt ist etwa das "Gruselkabinett".... ► Artikel lesen | |
| GILEAD SCIENCES | 86,67 | +0,10 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
| MERCK & CO | 95,40 | +0,10 % | Leichte Zugewinne bei der Merck & Co-Aktie (97,4751 €) | Im US-amerikanischen Wertpapierhandel liegt das Wertpapier von Merck & Co gegenwärtig im Plus. Das Wertpapier kostete zuletzt 101,34 US-Dollar. Für der Anteilsschein von Merck, inc steht gegenwärtig... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 434,35 | +0,32 % | Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock | ||
| EYEPOINT PHARMACEUTICALS | 8,616 | +0,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 8,950 | -3,24 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 14,550 | 0,00 % | Assembly Biosciences - Herpes-Wirkstoff übertrifft Erwartungen | Mein diesjähriger Top-Favorit Assembly Biosciences (WKN: A402CB) präsentierte gestern herausragende Studiendaten seines Wirkstoffkandidaten ABI-5366 zur Behandlung von wiederkehrendem Genitalherpes.... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,250 | -0,60 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| OPKO HEALTH | 1,500 | -0,83 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 115,00 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| ALTIMMUNE | 8,204 | -1,39 % | Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? | ||
| EXSCIENTIA | 4,520 | -1,74 % | XFRA 0RK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXSCIENTIA SP.ADRS... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 122,05 | +0,33 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract ... | Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response... ► Artikel lesen | |
| ROCKET LAB USA | 22,350 | 0,00 % | Where Will Rocket Lab Be in 3 Years? | ||
| ROYALTY PHARMA | 25,450 | +0,35 % | Dividendenbekanntmachungen (15.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,7 USD 0,6646 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0712 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen |
Das Unternehmen MILESTONE PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,810 Euro und damit -2,16 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
